The identification of functional domains within ANRIL addresses the challenge posed by its lengthy nucleotide sequences, thereby enhancing its potential as a targeted therapeutic agent for treating pulmonary fibrosis. The gene discussed is CDKN2B-AS1; the disease is pulmonary fibrosis.